Search 

Cello Health BioConsulting, previously Defined Health, is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. We provide strategic advice for corporate growth strategy, disease area selection, indication prioritization, early market access strategy and early value profile development. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent,
objective and actionable strategic advice to realize value across all therapeutic areas and stages of
development.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.

China Meheco Group Co., Ltd. (China Meheco), established in 1984, head office in Beijing. State-owned company listed at Shanghai Stock Exchange (No 600056).
The whole industry chain includes R&D, cultivation & processing, manufacturing, distribution, logistics, international trading, academic promotion, technical service etc.
The company has established a comprehensive business framework supported by pharmaceutical manufacture. The 12 drug plants of the Group system China Meheco are located in different regions in China. All production lines are proved by GMP, Good Manufacturing Practice, etc.

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.

CUBIC is the ultimate platform for emerging and growing companies seeking to expand their market to China or establish a business presence in China through various services and programs fitting every clients' needs and stage. When vacationing abroad, your best guide is a native, and business is no different. As CUBIC is owned by one of the largest Chinese incubator Thinkzone, you can be confident that you will be benefiting from one of the most extensive and influential networks in China.

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.

Deutsche Bank is the largest bank in Germany and one of only 4 Depositary Receipt banks able to list Life Sciences and Medtech companies on US exchanges using ADRs.

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.